Huntington’s disease families weigh daily decline against a first gene therapy breakthrough
Romy Kerschbaumer’s story begins with a diagnosis, but it is really a portrait of what Huntington’s disease does to an entire household. She was 48 when symptoms forced her to medically retire from the IT strategy job she loved in Jersey, and the illness has steadily reshaped her mind, mobility and independence over the past 10 years. Her two adult children now live at home and have become more hands-on as she loses the ability to manage ordinary tasks she once handled without thought.
The disease is inherited, progressive and unforgiving. In the UK, about 1 in 10,000 people live with Huntington’s, a condition caused by an error in the huntingtin gene. First symptoms usually emerge in the 30s or 40s, and the illness typically progresses across cognition, mood and movement before becoming fatal within about two decades. If a parent carries the altered gene, each child faces a 50% chance of inheriting it.
For Romy, the diagnosis was followed by a decision to keep life moving as normally as possible for as long as she could. She continued taking her daughter to dancing and her son to football, trying to avoid letting the illness dominate the family’s daily rhythm. That effort has become harder as the disease advances. She now describes doing only the very minimum, because the condition has taken so much.
One sentence captures the brutality of the disorder better than any clinical summary: there is no hiding from a gene that keeps unfolding its damage over time.
Brain cell loss, family strain and the slow erosion of independence
Huntington’s disease kills brain cells relentlessly, and the clinical picture often resembles a blend of dementia, Parkinson’s disease and motor neurone disease. The biology explains the lived experience. As neurons die, patients lose fine motor control, emotional stability and the cognitive flexibility needed to manage work, relationships and routine domestic life. Brain scans can show the difference starkly, with loss of brain tissue visible where healthy neuronal networks have already disappeared.
Romy’s account also makes clear that the disease reaches beyond the patient. Sofia, her 21-year-old daughter, describes her mother as a hero, and the family’s language is full of mutual protection. Her brother Joe and Sofia live at home, partly to care for their mother as her needs increase. When Romy has a bad day, the whole household feels it. The emotional burden is not abstract, and it does not stay confined to clinic appointments or scan results.
Living with Huntington’s has affected Romy emotionally and psychologically, but she says it has not taken away her Austrian spirit. That phrasing may sound simple, yet it reflects a common truth in neurodegenerative disease: identity can persist even as function recedes. Patients often remain sharply aware of what they are losing, which can make the psychological toll as severe as the neurological one.
Sparse specialist care in Jersey leaves a gap in support
Romy says she has had good support from her GP, yet Jersey does not have a Huntington’s specialist doctor. Sofia said a new consultant neurologist only recently started work after the previous one retired, leaving the family with little specialist input apart from medication adjustments. The gaps matter because Huntington’s care usually requires more than symptom control. Patients need coordinated support for movement problems, mood symptoms, communication changes, caregiver strain and future planning.
In a condition this complex, fragmented care can leave families uncertain about what they are missing. Sofia’s remark carries real clinical weight: when specialist services are thin, patients may not know which therapies, assessments or support networks could improve quality of life. Huntington’s care is rarely a one-drug problem. It depends on sustained multidisciplinary follow-up, and that is especially difficult in smaller health systems.
Romy has tried to expand her own support network by contacting others living with Huntington’s disease on social media and creating a WhatsApp group. For a rare disorder, that kind of peer connection can be clinically relevant as well as emotionally restorative. It gives patients language for symptoms, strategies for coping and a sense that they are not the only ones navigating a disease that can isolate families long before it becomes physically disabling.
A gene therapy result has changed the emotional calculus
Last year brought the first successful treatment result for Huntington’s disease, when doctors at University College London reported a gene therapy that slowed disease progression by 75%. For a disorder defined by relentless neurodegeneration, that figure carried enormous symbolic and scientific weight. It did not erase the diagnosis, but it changed the emotional arithmetic for families who had lived with only decline and inheritance risk.
Romy said the news left her elated. The hope, she said, keeps her going on the darkest days. Her daughter responded in equally direct terms: the breakthrough offers younger generations a chance not to go through what this family has endured. In Huntington’s disease, where the threat is passed from parent to child with a 50% probability, the possibility of disease modification is not just a research milestone. It changes how families imagine the future.
Cath Stanley, chief executive of the Huntington’s Disease Association, described the breakthrough as generating excitement and opportunity while stressing that there is still a long way to go. That is the correct frame. A 75% slowing of progression is extraordinary, but Huntington’s remains a devastating inherited neurodegenerative disease, and one successful trial does not eliminate the need for broader access, longer follow-up and additional research paths.
Sofia is now planning to run the London Marathon next year for the Huntington’s Disease Association, using the race to raise money and awareness. The family’s response to the diagnosis has become part activism, part survival strategy. They are trying to turn a condition built on fear and inevitability into something else: visibility, support and the stubborn belief that more than one scientific route may still lead to a treatment that changes lives.